Hormonal contraceptives and breast cancer: Clinical data
The endocrine background of breast cancer has raised questions about the increase in risk that might bear the use of hormonal contraceptives. This has been a particular issue in the case of young women, who constitute the population of contraceptive consumers. Observational studies have been the mai...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Zolfaroli, Irene [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2018transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
5 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Shelter seeking behaviour of healthy donkeys and mules in a hot climate - Haddy, Emily ELSEVIER, 2019, the official journal of the European Association of Gynaecologists and Obstetricians (EAGO) & the European College of Obstetrics and Gynaecology (EBCOG), Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:230 ; year:2018 ; pages:212-216 ; extent:5 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.ejogrb.2018.03.058 |
|---|
| Katalog-ID: |
ELV044911289 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV044911289 | ||
| 003 | DE-627 | ||
| 005 | 20230626005956.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 181123s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejogrb.2018.03.058 |2 doi | |
| 028 | 5 | 2 | |a GBV00000000000425.pica |
| 035 | |a (DE-627)ELV044911289 | ||
| 035 | |a (ELSEVIER)S0301-2115(18)30156-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 590 |q VZ |
| 084 | |a 12 |a 22 |2 ssgn | ||
| 084 | |a BIODIV |q DE-30 |2 fid | ||
| 084 | |a 42.66 |2 bkl | ||
| 100 | 1 | |a Zolfaroli, Irene |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hormonal contraceptives and breast cancer: Clinical data |
| 264 | 1 | |c 2018transfer abstract | |
| 300 | |a 5 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a The endocrine background of breast cancer has raised questions about the increase in risk that might bear the use of hormonal contraceptives. This has been a particular issue in the case of young women, who constitute the population of contraceptive consumers. Observational studies have been the main source of evidence, which has mainly limited to the combined estrogen-progestogen preparations, the popular pill. Studies in the 80′s and 90′s of the past century found a small, around a 20%, increase in risk. The translation in absolute number of excess cases has been exiguous because the prevalence of the disease is relatively small in premenopausal women. Moreover, the risk slowly seemed to disappear after 5–10 years of use. | ||
| 520 | |a The endocrine background of breast cancer has raised questions about the increase in risk that might bear the use of hormonal contraceptives. This has been a particular issue in the case of young women, who constitute the population of contraceptive consumers. Observational studies have been the main source of evidence, which has mainly limited to the combined estrogen-progestogen preparations, the popular pill. Studies in the 80′s and 90′s of the past century found a small, around a 20%, increase in risk. The translation in absolute number of excess cases has been exiguous because the prevalence of the disease is relatively small in premenopausal women. Moreover, the risk slowly seemed to disappear after 5–10 years of use. | ||
| 650 | 7 | |a Hormonal contraceptives |2 Elsevier | |
| 650 | 7 | |a Young women |2 Elsevier | |
| 650 | 7 | |a Breast cancer |2 Elsevier | |
| 700 | 1 | |a Tarín, Juan J. |4 oth | |
| 700 | 1 | |a Cano, Antonio |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Haddy, Emily ELSEVIER |t Shelter seeking behaviour of healthy donkeys and mules in a hot climate |d 2019 |d the official journal of the European Association of Gynaecologists and Obstetricians (EAGO) & the European College of Obstetrics and Gynaecology (EBCOG) |g Amsterdam [u.a.] |w (DE-627)ELV00344807X |
| 773 | 1 | 8 | |g volume:230 |g year:2018 |g pages:212-216 |g extent:5 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ejogrb.2018.03.058 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a FID-BIODIV | ||
| 936 | b | k | |a 42.66 |j Ethologie |x Biologie |q VZ |
| 951 | |a AR | ||
| 952 | |d 230 |j 2018 |h 212-216 |g 5 | ||
| author_variant |
i z iz |
|---|---|
| matchkey_str |
zolfaroliirenetarnjuanjcanoantonio:2018----:omnlotaetvsnbescne |
| hierarchy_sort_str |
2018transfer abstract |
| bklnumber |
42.66 |
| publishDate |
2018 |
| allfields |
10.1016/j.ejogrb.2018.03.058 doi GBV00000000000425.pica (DE-627)ELV044911289 (ELSEVIER)S0301-2115(18)30156-8 DE-627 ger DE-627 rakwb eng 590 VZ 12 22 ssgn BIODIV DE-30 fid 42.66 bkl Zolfaroli, Irene verfasserin aut Hormonal contraceptives and breast cancer: Clinical data 2018transfer abstract 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The endocrine background of breast cancer has raised questions about the increase in risk that might bear the use of hormonal contraceptives. This has been a particular issue in the case of young women, who constitute the population of contraceptive consumers. Observational studies have been the main source of evidence, which has mainly limited to the combined estrogen-progestogen preparations, the popular pill. Studies in the 80′s and 90′s of the past century found a small, around a 20%, increase in risk. The translation in absolute number of excess cases has been exiguous because the prevalence of the disease is relatively small in premenopausal women. Moreover, the risk slowly seemed to disappear after 5–10 years of use. The endocrine background of breast cancer has raised questions about the increase in risk that might bear the use of hormonal contraceptives. This has been a particular issue in the case of young women, who constitute the population of contraceptive consumers. Observational studies have been the main source of evidence, which has mainly limited to the combined estrogen-progestogen preparations, the popular pill. Studies in the 80′s and 90′s of the past century found a small, around a 20%, increase in risk. The translation in absolute number of excess cases has been exiguous because the prevalence of the disease is relatively small in premenopausal women. Moreover, the risk slowly seemed to disappear after 5–10 years of use. Hormonal contraceptives Elsevier Young women Elsevier Breast cancer Elsevier Tarín, Juan J. oth Cano, Antonio oth Enthalten in Elsevier Science Haddy, Emily ELSEVIER Shelter seeking behaviour of healthy donkeys and mules in a hot climate 2019 the official journal of the European Association of Gynaecologists and Obstetricians (EAGO) & the European College of Obstetrics and Gynaecology (EBCOG) Amsterdam [u.a.] (DE-627)ELV00344807X volume:230 year:2018 pages:212-216 extent:5 https://doi.org/10.1016/j.ejogrb.2018.03.058 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV 42.66 Ethologie Biologie VZ AR 230 2018 212-216 5 |
| spelling |
10.1016/j.ejogrb.2018.03.058 doi GBV00000000000425.pica (DE-627)ELV044911289 (ELSEVIER)S0301-2115(18)30156-8 DE-627 ger DE-627 rakwb eng 590 VZ 12 22 ssgn BIODIV DE-30 fid 42.66 bkl Zolfaroli, Irene verfasserin aut Hormonal contraceptives and breast cancer: Clinical data 2018transfer abstract 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The endocrine background of breast cancer has raised questions about the increase in risk that might bear the use of hormonal contraceptives. This has been a particular issue in the case of young women, who constitute the population of contraceptive consumers. Observational studies have been the main source of evidence, which has mainly limited to the combined estrogen-progestogen preparations, the popular pill. Studies in the 80′s and 90′s of the past century found a small, around a 20%, increase in risk. The translation in absolute number of excess cases has been exiguous because the prevalence of the disease is relatively small in premenopausal women. Moreover, the risk slowly seemed to disappear after 5–10 years of use. The endocrine background of breast cancer has raised questions about the increase in risk that might bear the use of hormonal contraceptives. This has been a particular issue in the case of young women, who constitute the population of contraceptive consumers. Observational studies have been the main source of evidence, which has mainly limited to the combined estrogen-progestogen preparations, the popular pill. Studies in the 80′s and 90′s of the past century found a small, around a 20%, increase in risk. The translation in absolute number of excess cases has been exiguous because the prevalence of the disease is relatively small in premenopausal women. Moreover, the risk slowly seemed to disappear after 5–10 years of use. Hormonal contraceptives Elsevier Young women Elsevier Breast cancer Elsevier Tarín, Juan J. oth Cano, Antonio oth Enthalten in Elsevier Science Haddy, Emily ELSEVIER Shelter seeking behaviour of healthy donkeys and mules in a hot climate 2019 the official journal of the European Association of Gynaecologists and Obstetricians (EAGO) & the European College of Obstetrics and Gynaecology (EBCOG) Amsterdam [u.a.] (DE-627)ELV00344807X volume:230 year:2018 pages:212-216 extent:5 https://doi.org/10.1016/j.ejogrb.2018.03.058 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV 42.66 Ethologie Biologie VZ AR 230 2018 212-216 5 |
| allfields_unstemmed |
10.1016/j.ejogrb.2018.03.058 doi GBV00000000000425.pica (DE-627)ELV044911289 (ELSEVIER)S0301-2115(18)30156-8 DE-627 ger DE-627 rakwb eng 590 VZ 12 22 ssgn BIODIV DE-30 fid 42.66 bkl Zolfaroli, Irene verfasserin aut Hormonal contraceptives and breast cancer: Clinical data 2018transfer abstract 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The endocrine background of breast cancer has raised questions about the increase in risk that might bear the use of hormonal contraceptives. This has been a particular issue in the case of young women, who constitute the population of contraceptive consumers. Observational studies have been the main source of evidence, which has mainly limited to the combined estrogen-progestogen preparations, the popular pill. Studies in the 80′s and 90′s of the past century found a small, around a 20%, increase in risk. The translation in absolute number of excess cases has been exiguous because the prevalence of the disease is relatively small in premenopausal women. Moreover, the risk slowly seemed to disappear after 5–10 years of use. The endocrine background of breast cancer has raised questions about the increase in risk that might bear the use of hormonal contraceptives. This has been a particular issue in the case of young women, who constitute the population of contraceptive consumers. Observational studies have been the main source of evidence, which has mainly limited to the combined estrogen-progestogen preparations, the popular pill. Studies in the 80′s and 90′s of the past century found a small, around a 20%, increase in risk. The translation in absolute number of excess cases has been exiguous because the prevalence of the disease is relatively small in premenopausal women. Moreover, the risk slowly seemed to disappear after 5–10 years of use. Hormonal contraceptives Elsevier Young women Elsevier Breast cancer Elsevier Tarín, Juan J. oth Cano, Antonio oth Enthalten in Elsevier Science Haddy, Emily ELSEVIER Shelter seeking behaviour of healthy donkeys and mules in a hot climate 2019 the official journal of the European Association of Gynaecologists and Obstetricians (EAGO) & the European College of Obstetrics and Gynaecology (EBCOG) Amsterdam [u.a.] (DE-627)ELV00344807X volume:230 year:2018 pages:212-216 extent:5 https://doi.org/10.1016/j.ejogrb.2018.03.058 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV 42.66 Ethologie Biologie VZ AR 230 2018 212-216 5 |
| allfieldsGer |
10.1016/j.ejogrb.2018.03.058 doi GBV00000000000425.pica (DE-627)ELV044911289 (ELSEVIER)S0301-2115(18)30156-8 DE-627 ger DE-627 rakwb eng 590 VZ 12 22 ssgn BIODIV DE-30 fid 42.66 bkl Zolfaroli, Irene verfasserin aut Hormonal contraceptives and breast cancer: Clinical data 2018transfer abstract 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The endocrine background of breast cancer has raised questions about the increase in risk that might bear the use of hormonal contraceptives. This has been a particular issue in the case of young women, who constitute the population of contraceptive consumers. Observational studies have been the main source of evidence, which has mainly limited to the combined estrogen-progestogen preparations, the popular pill. Studies in the 80′s and 90′s of the past century found a small, around a 20%, increase in risk. The translation in absolute number of excess cases has been exiguous because the prevalence of the disease is relatively small in premenopausal women. Moreover, the risk slowly seemed to disappear after 5–10 years of use. The endocrine background of breast cancer has raised questions about the increase in risk that might bear the use of hormonal contraceptives. This has been a particular issue in the case of young women, who constitute the population of contraceptive consumers. Observational studies have been the main source of evidence, which has mainly limited to the combined estrogen-progestogen preparations, the popular pill. Studies in the 80′s and 90′s of the past century found a small, around a 20%, increase in risk. The translation in absolute number of excess cases has been exiguous because the prevalence of the disease is relatively small in premenopausal women. Moreover, the risk slowly seemed to disappear after 5–10 years of use. Hormonal contraceptives Elsevier Young women Elsevier Breast cancer Elsevier Tarín, Juan J. oth Cano, Antonio oth Enthalten in Elsevier Science Haddy, Emily ELSEVIER Shelter seeking behaviour of healthy donkeys and mules in a hot climate 2019 the official journal of the European Association of Gynaecologists and Obstetricians (EAGO) & the European College of Obstetrics and Gynaecology (EBCOG) Amsterdam [u.a.] (DE-627)ELV00344807X volume:230 year:2018 pages:212-216 extent:5 https://doi.org/10.1016/j.ejogrb.2018.03.058 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV 42.66 Ethologie Biologie VZ AR 230 2018 212-216 5 |
| allfieldsSound |
10.1016/j.ejogrb.2018.03.058 doi GBV00000000000425.pica (DE-627)ELV044911289 (ELSEVIER)S0301-2115(18)30156-8 DE-627 ger DE-627 rakwb eng 590 VZ 12 22 ssgn BIODIV DE-30 fid 42.66 bkl Zolfaroli, Irene verfasserin aut Hormonal contraceptives and breast cancer: Clinical data 2018transfer abstract 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The endocrine background of breast cancer has raised questions about the increase in risk that might bear the use of hormonal contraceptives. This has been a particular issue in the case of young women, who constitute the population of contraceptive consumers. Observational studies have been the main source of evidence, which has mainly limited to the combined estrogen-progestogen preparations, the popular pill. Studies in the 80′s and 90′s of the past century found a small, around a 20%, increase in risk. The translation in absolute number of excess cases has been exiguous because the prevalence of the disease is relatively small in premenopausal women. Moreover, the risk slowly seemed to disappear after 5–10 years of use. The endocrine background of breast cancer has raised questions about the increase in risk that might bear the use of hormonal contraceptives. This has been a particular issue in the case of young women, who constitute the population of contraceptive consumers. Observational studies have been the main source of evidence, which has mainly limited to the combined estrogen-progestogen preparations, the popular pill. Studies in the 80′s and 90′s of the past century found a small, around a 20%, increase in risk. The translation in absolute number of excess cases has been exiguous because the prevalence of the disease is relatively small in premenopausal women. Moreover, the risk slowly seemed to disappear after 5–10 years of use. Hormonal contraceptives Elsevier Young women Elsevier Breast cancer Elsevier Tarín, Juan J. oth Cano, Antonio oth Enthalten in Elsevier Science Haddy, Emily ELSEVIER Shelter seeking behaviour of healthy donkeys and mules in a hot climate 2019 the official journal of the European Association of Gynaecologists and Obstetricians (EAGO) & the European College of Obstetrics and Gynaecology (EBCOG) Amsterdam [u.a.] (DE-627)ELV00344807X volume:230 year:2018 pages:212-216 extent:5 https://doi.org/10.1016/j.ejogrb.2018.03.058 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV 42.66 Ethologie Biologie VZ AR 230 2018 212-216 5 |
| language |
English |
| source |
Enthalten in Shelter seeking behaviour of healthy donkeys and mules in a hot climate Amsterdam [u.a.] volume:230 year:2018 pages:212-216 extent:5 |
| sourceStr |
Enthalten in Shelter seeking behaviour of healthy donkeys and mules in a hot climate Amsterdam [u.a.] volume:230 year:2018 pages:212-216 extent:5 |
| format_phy_str_mv |
Article |
| bklname |
Ethologie |
| institution |
findex.gbv.de |
| topic_facet |
Hormonal contraceptives Young women Breast cancer |
| dewey-raw |
590 |
| isfreeaccess_bool |
false |
| container_title |
Shelter seeking behaviour of healthy donkeys and mules in a hot climate |
| authorswithroles_txt_mv |
Zolfaroli, Irene @@aut@@ Tarín, Juan J. @@oth@@ Cano, Antonio @@oth@@ |
| publishDateDaySort_date |
2018-01-01T00:00:00Z |
| hierarchy_top_id |
ELV00344807X |
| dewey-sort |
3590 |
| id |
ELV044911289 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV044911289</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626005956.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">181123s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ejogrb.2018.03.058</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000425.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV044911289</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0301-2115(18)30156-8</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">590</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">12</subfield><subfield code="a">22</subfield><subfield code="2">ssgn</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">BIODIV</subfield><subfield code="q">DE-30</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">42.66</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Zolfaroli, Irene</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Hormonal contraceptives and breast cancer: Clinical data</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">5</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The endocrine background of breast cancer has raised questions about the increase in risk that might bear the use of hormonal contraceptives. This has been a particular issue in the case of young women, who constitute the population of contraceptive consumers. Observational studies have been the main source of evidence, which has mainly limited to the combined estrogen-progestogen preparations, the popular pill. Studies in the 80′s and 90′s of the past century found a small, around a 20%, increase in risk. The translation in absolute number of excess cases has been exiguous because the prevalence of the disease is relatively small in premenopausal women. Moreover, the risk slowly seemed to disappear after 5–10 years of use.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The endocrine background of breast cancer has raised questions about the increase in risk that might bear the use of hormonal contraceptives. This has been a particular issue in the case of young women, who constitute the population of contraceptive consumers. Observational studies have been the main source of evidence, which has mainly limited to the combined estrogen-progestogen preparations, the popular pill. Studies in the 80′s and 90′s of the past century found a small, around a 20%, increase in risk. The translation in absolute number of excess cases has been exiguous because the prevalence of the disease is relatively small in premenopausal women. Moreover, the risk slowly seemed to disappear after 5–10 years of use.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Hormonal contraceptives</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Young women</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Breast cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tarín, Juan J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cano, Antonio</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Haddy, Emily ELSEVIER</subfield><subfield code="t">Shelter seeking behaviour of healthy donkeys and mules in a hot climate</subfield><subfield code="d">2019</subfield><subfield code="d">the official journal of the European Association of Gynaecologists and Obstetricians (EAGO) & the European College of Obstetrics and Gynaecology (EBCOG)</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV00344807X</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:230</subfield><subfield code="g">year:2018</subfield><subfield code="g">pages:212-216</subfield><subfield code="g">extent:5</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ejogrb.2018.03.058</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-BIODIV</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">42.66</subfield><subfield code="j">Ethologie</subfield><subfield code="x">Biologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">230</subfield><subfield code="j">2018</subfield><subfield code="h">212-216</subfield><subfield code="g">5</subfield></datafield></record></collection>
|
| author |
Zolfaroli, Irene |
| spellingShingle |
Zolfaroli, Irene ddc 590 ssgn 12 fid BIODIV bkl 42.66 Elsevier Hormonal contraceptives Elsevier Young women Elsevier Breast cancer Hormonal contraceptives and breast cancer: Clinical data |
| authorStr |
Zolfaroli, Irene |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV00344807X |
| format |
electronic Article |
| dewey-ones |
590 - Animals (Zoology) |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
590 VZ 12 22 ssgn BIODIV DE-30 fid 42.66 bkl Hormonal contraceptives and breast cancer: Clinical data Hormonal contraceptives Elsevier Young women Elsevier Breast cancer Elsevier |
| topic |
ddc 590 ssgn 12 fid BIODIV bkl 42.66 Elsevier Hormonal contraceptives Elsevier Young women Elsevier Breast cancer |
| topic_unstemmed |
ddc 590 ssgn 12 fid BIODIV bkl 42.66 Elsevier Hormonal contraceptives Elsevier Young women Elsevier Breast cancer |
| topic_browse |
ddc 590 ssgn 12 fid BIODIV bkl 42.66 Elsevier Hormonal contraceptives Elsevier Young women Elsevier Breast cancer |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
j j t jj jjt a c ac |
| hierarchy_parent_title |
Shelter seeking behaviour of healthy donkeys and mules in a hot climate |
| hierarchy_parent_id |
ELV00344807X |
| dewey-tens |
590 - Animals (Zoology) |
| hierarchy_top_title |
Shelter seeking behaviour of healthy donkeys and mules in a hot climate |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV00344807X |
| title |
Hormonal contraceptives and breast cancer: Clinical data |
| ctrlnum |
(DE-627)ELV044911289 (ELSEVIER)S0301-2115(18)30156-8 |
| title_full |
Hormonal contraceptives and breast cancer: Clinical data |
| author_sort |
Zolfaroli, Irene |
| journal |
Shelter seeking behaviour of healthy donkeys and mules in a hot climate |
| journalStr |
Shelter seeking behaviour of healthy donkeys and mules in a hot climate |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
500 - Science |
| recordtype |
marc |
| publishDateSort |
2018 |
| contenttype_str_mv |
zzz |
| container_start_page |
212 |
| author_browse |
Zolfaroli, Irene |
| container_volume |
230 |
| physical |
5 |
| class |
590 VZ 12 22 ssgn BIODIV DE-30 fid 42.66 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Zolfaroli, Irene |
| doi_str_mv |
10.1016/j.ejogrb.2018.03.058 |
| dewey-full |
590 |
| title_sort |
hormonal contraceptives and breast cancer: clinical data |
| title_auth |
Hormonal contraceptives and breast cancer: Clinical data |
| abstract |
The endocrine background of breast cancer has raised questions about the increase in risk that might bear the use of hormonal contraceptives. This has been a particular issue in the case of young women, who constitute the population of contraceptive consumers. Observational studies have been the main source of evidence, which has mainly limited to the combined estrogen-progestogen preparations, the popular pill. Studies in the 80′s and 90′s of the past century found a small, around a 20%, increase in risk. The translation in absolute number of excess cases has been exiguous because the prevalence of the disease is relatively small in premenopausal women. Moreover, the risk slowly seemed to disappear after 5–10 years of use. |
| abstractGer |
The endocrine background of breast cancer has raised questions about the increase in risk that might bear the use of hormonal contraceptives. This has been a particular issue in the case of young women, who constitute the population of contraceptive consumers. Observational studies have been the main source of evidence, which has mainly limited to the combined estrogen-progestogen preparations, the popular pill. Studies in the 80′s and 90′s of the past century found a small, around a 20%, increase in risk. The translation in absolute number of excess cases has been exiguous because the prevalence of the disease is relatively small in premenopausal women. Moreover, the risk slowly seemed to disappear after 5–10 years of use. |
| abstract_unstemmed |
The endocrine background of breast cancer has raised questions about the increase in risk that might bear the use of hormonal contraceptives. This has been a particular issue in the case of young women, who constitute the population of contraceptive consumers. Observational studies have been the main source of evidence, which has mainly limited to the combined estrogen-progestogen preparations, the popular pill. Studies in the 80′s and 90′s of the past century found a small, around a 20%, increase in risk. The translation in absolute number of excess cases has been exiguous because the prevalence of the disease is relatively small in premenopausal women. Moreover, the risk slowly seemed to disappear after 5–10 years of use. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV |
| title_short |
Hormonal contraceptives and breast cancer: Clinical data |
| url |
https://doi.org/10.1016/j.ejogrb.2018.03.058 |
| remote_bool |
true |
| author2 |
Tarín, Juan J. Cano, Antonio |
| author2Str |
Tarín, Juan J. Cano, Antonio |
| ppnlink |
ELV00344807X |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth |
| doi_str |
10.1016/j.ejogrb.2018.03.058 |
| up_date |
2024-07-06T22:43:47.090Z |
| _version_ |
1803871402947772416 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV044911289</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626005956.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">181123s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ejogrb.2018.03.058</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000425.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV044911289</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0301-2115(18)30156-8</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">590</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">12</subfield><subfield code="a">22</subfield><subfield code="2">ssgn</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">BIODIV</subfield><subfield code="q">DE-30</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">42.66</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Zolfaroli, Irene</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Hormonal contraceptives and breast cancer: Clinical data</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">5</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The endocrine background of breast cancer has raised questions about the increase in risk that might bear the use of hormonal contraceptives. This has been a particular issue in the case of young women, who constitute the population of contraceptive consumers. Observational studies have been the main source of evidence, which has mainly limited to the combined estrogen-progestogen preparations, the popular pill. Studies in the 80′s and 90′s of the past century found a small, around a 20%, increase in risk. The translation in absolute number of excess cases has been exiguous because the prevalence of the disease is relatively small in premenopausal women. Moreover, the risk slowly seemed to disappear after 5–10 years of use.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The endocrine background of breast cancer has raised questions about the increase in risk that might bear the use of hormonal contraceptives. This has been a particular issue in the case of young women, who constitute the population of contraceptive consumers. Observational studies have been the main source of evidence, which has mainly limited to the combined estrogen-progestogen preparations, the popular pill. Studies in the 80′s and 90′s of the past century found a small, around a 20%, increase in risk. The translation in absolute number of excess cases has been exiguous because the prevalence of the disease is relatively small in premenopausal women. Moreover, the risk slowly seemed to disappear after 5–10 years of use.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Hormonal contraceptives</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Young women</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Breast cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tarín, Juan J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cano, Antonio</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Haddy, Emily ELSEVIER</subfield><subfield code="t">Shelter seeking behaviour of healthy donkeys and mules in a hot climate</subfield><subfield code="d">2019</subfield><subfield code="d">the official journal of the European Association of Gynaecologists and Obstetricians (EAGO) & the European College of Obstetrics and Gynaecology (EBCOG)</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV00344807X</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:230</subfield><subfield code="g">year:2018</subfield><subfield code="g">pages:212-216</subfield><subfield code="g">extent:5</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ejogrb.2018.03.058</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-BIODIV</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">42.66</subfield><subfield code="j">Ethologie</subfield><subfield code="x">Biologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">230</subfield><subfield code="j">2018</subfield><subfield code="h">212-216</subfield><subfield code="g">5</subfield></datafield></record></collection>
|
| score |
7.3994513 |